Hemerion and Mount Sinai Health System (NYC) are collaborating to launch an ambitious clinical trial in 2022. This collaboration has won the “Best Collaboration in the MedTech and Digital Health” award of the Galien Medstartup Prize: an international recognition that perfectly kickstarts the Hemerion development in the USA.  The Galien Medstartup fosters, recognizes and rewards …

Hemerion and Mount Sinai Health System have been nominated for the 8th edition of the Galien MedStartUp Awards, the innovation prize created by the Galien Foundation and Business France. The Galien Medstartup fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Since 2013, it supports the international development of …

The Hemerion technology, which associates drugs and photonic treatments against glioblastoma, is to be evaluated in the DOSINDYGO clinical trial.This new clinical trial is sponsored by CHU de Lille (PI Nicolas REYNS) and the Brussels Erasmus Hospital (PI Florence Lefranc) with the financial support of Fonds Erasme. Following the INDYGO trial which assessed the Hemerion …

Pr. Nicolas Reyns, Head of the neurosurgery oncology dept. of the University Hospital of Lille, has been developing photodynamic therapy since 2010 in partnership with the Inserm laboratory U1189 OncoThAI. He notably spearheaded ground-breaking glioblastoma treatments and co-invented the technology now developed by Hemerion. Pr. Reyns has presented his experience developing photodynamic therapy for glioblastoma …

On Saturday, March 20, 2021, the Journal of Neuro-Oncology published the first clinical results of the technology developed by Hemerion for the treatment of glioblastoma, one of the most common and aggressive brain cancers.These results demonstrate high tolerance of the treatment and are very encouraging in terms of efficacy: a validation that paves the way …